News

June 9, 2022
MRI Assisted Radiosurgery (MARS) Utilizing C4 Imaging’s Sirius ® Positive-Signal MRI Markers Provides Detailed Anatomic Information for Prostate Cancer Treatment

C4 Imaging LLC is pleased to note that a publication in the American Brachytherapy Society’s journal, Brachytherapy, concluded that MRI assisted radiosurgery utilizing Sirius, is a valuable approach to prostate brachytherapy, as it provides detailed anatomic information for treatment planning and delivery, as well as for quality assurance.
May 31, 2022
C4 Imaging Announces First Prostate Cancer Treatments Utilizing NovaTM Fiducial Markers

C4 Imaging LLC is pleased to announce the first prostate cancer treatments utilizing NovaTM, a multimodality fiducial marker designed to maximize MRI utility in improving the accuracy of cancer treatment. The procedures were performed by Dr Peter Rossi and Dr David Marcus, radiation oncologists, at Valley View’s Calaway • Young Cancer Center in Glenwood Springs, Colorado.
May 31, 2022
C4 Imaging Announces Addition to Board of Directors

C4 Imaging LLC, an early-stage medical device company, has announced that Jeff Seavey has been elected to the company's Board of Directors. Jeff joins the C4 Imaging Board with over 25 years of success in the development and commercialization of medical devices.
February 16, 2022
C4 Imaging Announces First Cancer Treatment Utilizing Orion HDR MRI Markers In New Mexico

C4 Imaging LLC is pleased to announce the first cancer treatment in New Mexico utilizing OrionTM, a novel medical device that’s designed to facilitate the use of MRI in improving the accuracy of treatment. The procedure was performed by Gregg E. Franklin MD, PhD, Radiation Oncologist at New Mexico Cancer Center.
February 11, 2021
C4 Imaging Announces Successful Completion of an Institutional Financing Round

C4 Imaging LLC, an early-stage medical device company, has completed its latest round of financing, which included a significant institutional component. Institutional investment was led by Stoneworth Financial, LLC, a Houston based investment banking group. Proceeds will be used for growth capital, targeted at accelerating clinical adoption of C4 Imaging’s portfolio of FDA cleared products developed around its unique encapsulated positive-signal MRI technology. In addition, funds will be used to complete the development of a new generation of medical devices designed to improve MRI utilization in the breast biopsy market.
January 5, 2021
C4 Imaging Announces Sirius Positive Signal MRI Marker Given FDA 510(k) Clearance for Use with Isoray’s Cesium-131 Brachytherapy Seeds to Treat Prostate Cancer

C4 Imaging LLC is pleased to announce that Isoray Medical, Inc. (NYSE American: ISR) has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the use of C4 Imaging’s Sirius® positive-signal MRI (Magnetic Resonance Imaging) Markers with Isoray’s Cesium-131, brachytherapy seeds.
October 26, 2020
C4 Imaging Announces FDA 510(k) Clearance of its Non-metallic, Multimodality C4 Fiducial Marker

C4 Imaging LLC announces U.S. Food and Drug Administration 510(k) clearance of its third major product, the Multimodality C4 Fiducial Marker. This novel positive-signal MRI marker will be implanted into patients in situations where the location of specific anatomy, normal or diseased, needs to be marked for a future medical procedure. The device can be visualized using MRI, CT or x-ray, and provides a reference from which other procedures can be guided, for example during the treatment of cancer with radiotherapy.cal device that’s designed to facilitate the use of MRI in improving the accuracy of treatment. The procedure was performed by Dr Peter Rossi at the Calaway Young Cancer Center in Glenwood Springs, Colorado.
September 11, 2019
C4 Imaging Announces First Prostate Cancer Treatment Utilizing Orion™ HDR MRI Markers

C4 Imaging LLC is pleased to announce the first prostate cancer treatment utilizing Orion™, a novel medical device that’s designed to facilitate the use of MRI in improving the accuracy of treatment. The procedure was performed by Dr Peter Rossi at the Calaway Young Cancer Center in Glenwood Springs, Colorado.
September 12, 2018
Theragenics to Provide Sales and Marketing for C4 Imaging's New Orion™ HDR MRI Markers

Theragenics Corporation®, a medical device company serving the cancer treatment market, will provide sales and marketing for C4 Imaging’s novel, Orion™ Positive-Signal HDR MRI Lumen Marker. The marker is used prior to high dose rate (HDR) brachytherapy to accurately locate the position of the applicators that guide the placement of radioactive sources for the treatment of multiple cancers, including gynecological cancers. Using the superior imaging properties of MRI, the applicators can be positioned more precisely allowing for more accurate delivery of radiation to the tumor site while avoiding healthy surrounding organs and tissue. C4 Imaging recently received FDA 510(k) clearance for Orion™.
May 8, 2018
C4 Imaging Announces FDA 510(k) Clearance of its Positive-Signal High Dose Rate (HDR) Brachytherapy MRI Treatment Planning Marker

C4 Imaging LLC announces U.S. Food and Drug Administration 510(k) clearance of its second major brachytherapy product, the HDR MRI Marker. This novel, Positive-Signal MRI Marker will be used prior to high dose rate (HDR) brachytherapy to accurately locate the position of the applicators that guide the placement of radioactive sources for the treatment of multiple cancers.
September 5, 2017
C4 Imaging Announces an Additional FDA 510(k) Clearance for its Positive-Signal MRI Marker - Sirius™

C4 Imaging LLC is pleased to announce an additional US Food and Drug Administration 510(k) clearance for its Sirius™ MRI Marker, a novel positive-signal MRI Marker that is used during the treatment of prostate cancer with brachytherapy.
August 7, 2017
MRI Assisted Radiosurgery (MARS) Utilizing C4 Imaging’s Sirius™ Positive-Signal MRI Marker is a Cost-Effective Option for the Treatment of Prostate Cancer

C4 Imaging LLC announced today that the American Brachytherapy Society’s journal, Brachytherapy, has published a special issue focused on MRI-based prostate brachytherapy¹. This issue contains 15 individual papers describing all elements of MRI-based prostate brachytherapy, from key clinical techniques to the efficacy and cost effectiveness of the procedure.
Dec 22, 2016
C4 Imaging to Present at the Medtech Showcase 2017 (PDF)

C4 Imaging LLC today announced that President and CEO, Andrew Bright, will present at the Medtech Showcase 2017 (A Biotech Showcase^™), taking place at the Parc 55 Hotel in San Francisco, January 10 – 11. He is scheduled to speak on Tuesday, January 10 at 9.30am PST and will review current and future applications of C4 Imaging’s unique MRI contrast technology. Also attending the Medtech showcase will be Dr. Steven Frank, Chairman and Founder of C4 imaging. Dr.Frank is a Professor in the Department of Radiation Oncology at The University of Texas MD Anderson Cancer Center in Houston, Texas. He is Medical Director at the Proton Therapy Center and Director of Advanced Technologies for the Department of Radiation Oncology.
Jul 5, 2016
Clinical Study Discusses the Value of C4 Imaging’s Sirius^™ Positive-Signal MRI Marker in MRI-Guided Prostate Cancer Treatment (PDF)

C4 Imaging LLC today announced the presentation of a clinical study describing the use of Magnetic Resonance Imaging (MRI) in improving the quality of prostate cancer treatment. The data on 47 patients treated with prostate brachytherapy was presented at The World Congress of Brachytherapy meeting held in San Francisco, June 27 – 29, 2016.
Jun 6, 2016
C4 Imaging receives top honors at the 5th annual Texas Life Science Forum (PDF)

C4 Imaging LLC announced that it has been recognized as one of the Rice Alliance 10 Most Promising Life Science Companies at the 2016 Texas Life Science Forum hosted by the Rice Alliance for Technology and Entrepreneurship and BioHouston and Texas Healthcare and BioScience Institute at the BioScience Research Collaborative in Houston, May 26. The companies were chosen by industry experts and investors. More than 50 startup companies presented their business plan presentations at the forum. An additional six Nasdaq-listed life science companies provided status updates.
Sep 22, 2015
C4 Imaging Utilizes Evonik’s VESTAKEEP® PEEK For Prostate Cancer Device (PDF)

C4 Imaging LLC has chosen leading specialty chemicals company Evonik Corporation and its Resource Efficiency segment’s VESTAKEEP^® PEEK polymer technology in the design of Sirius^™, a recently developed Positive-Signal Magnetic Resonance Imaging (MRI) Marker used during the treatment of prostate cancer.
Aug 21, 2015
C4 Imaging Awarded $1.3 Million NIH SBIR Phase II Grant (PDF)

C4 Imaging LLC today announced it has been awarded a $1.32 Million Phase II Small Business Innovation Research (“SBIR”) grant from the National Cancer Institute of the National Institutes of Health (“NIH”). Entitled “Multi-Modality MRI/CT Markers for Improved Assessment of Prostate Cancer”, the Phase II SBIR award will help fund the development of an enhanced multi-modality imaging marker based on C4 Imaging’s commercially available Sirius^™ MRI Marker.
Apr 7, 2014
C4 Imaging Announces First SIRIUS^™ Positive Signal MRI Marker Implant (PDF)

“This first implant is a significant milestone,” said Andrew Bright, President and CEO of C4 Imaging. “MR imaging of the implanted Sirius^™ MRI Markers was successful and the clinical team were able to localize the implanted seeds.” He added, “We were delighted to partner with IsoRay™ Medical for this first implant.
Mar 31, 2014
C4 Imaging Signs SIRIUS^™ MRI MARKER Loading Services Agreement with AnazaoHealth Corporation (PDF)

C4 Imaging will partner with Florida-based AnazaoHealth Corporation, a leading provider of patient-specific prescription-loaded brachytherapy products for treating prostate cancer. Under the agreement AnazaoHealth will load the Sirius^™ MRI Marker alongside seeds into brachytherapy strands and needles according a physician prescription tailored to each individual patient.
Dec 6, 2013
C4 Imaging Announces FDA 510(k) Clearance of its Positive-Signal MRI Marker - Sirius^™ (PDF)

C4 Imaging LLC is pleased to announce U.S. Food and Drug Administration 510(k) clearance of its first product, the Sirius^™ MRI Marker. The novel positive-signal, MRI Marker will be used following treatment of prostate cancer with brachytherapy to facilitate seed localization within the prostate, utilizing a single post-implant Magnetic Resonance (MR) imaging procedure.